Stocktoria
MiNK Therapeutics, Inc. INKT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-10-15
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | -$30.2M |
| Operating cash flow | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M |
| Free cash flow | — | — | -$15.8M | -$19.1M | -$13.1M |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M |
| Shareholders' equity | -$14.2M | -$19.6M | -$18.1M | -$401,303 | $23.8M |
| Ratios | |||||
| Return on assets | -87.7% | -188.5% | -493.3% | -130.4% | -75.1% |
| Return on equity | 87.8% | 55.1% | 124.4% | 6975.1% | -127.1% |
| Current ratio | 1.06 | 0.72 | 0.32 | 1.61 | 2.41 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001840229 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.